Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Vasomotor Symptoms Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT04090957
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol oral tablet, Placebo oral tablet
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 3 Interventional Results available

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00755417
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2012 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional

Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women

NCT00511953
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release tablets, Gabapentin
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
8
States / cities
Burbank, California • DeLand, Florida • Port Orange, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer

NCT03646162
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Veru-944, Placebo
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
24
States / cities
Glendale, Arizona • Los Angeles, California • San Bernardino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2021 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of S-equol on Vasomotor Symptoms in Menopausal Patients

NCT00962585
View directory record Official record
Conditions
Menopause
Interventions
Placebo, S-equol
Drug
Lead sponsor
Ausio Pharmaceuticals, LLC
Industry
Eligibility
Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
5
States / cities
Louisville, Kentucky • Cincinnati, Ohio • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 4, 2026, 4:18 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Impact of Lean Pork on Endothelial Function in Perimenopause

NCT06976112
View directory record Official record
Conditions
Cardiovascular Outcome, Overweight and Obese Women, Perimenopausal Women, Vasomotor Symptoms (VMS)
Interventions
Pork Diet, Plant Diet
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
40 Years to 55 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 3 Interventional

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause

NCT00238732
View directory record Official record
Conditions
Vaginal Atrophy
Interventions
Bazedoxifene/Conjugated Estrogen
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
63
States / cities
Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2007 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
63
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Not applicable Interventional

Gabapentin For the Control of Hot Flashes in Women With Breast Cancer

NCT00022074
View directory record Official record
Conditions
Anxiety Disorder, Breast Cancer, Depression, Hot Flashes
Interventions
gabapentin, quality-of-life assessment
Drug · Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Up to 120 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
18
States / cities
Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Oct 4, 2026, 4:18 AM EDT
Completed No phase listed Observational

Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study

NCT01862861
View directory record Official record
Conditions
Menopause
Interventions
Not listed
Lead sponsor
Medimix Specialty Pharmacy, LLC
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effects of Synthetic Conjugated Estrogens, B (SCE-B) on Nocturnal Vasomotor Symptoms in Postmenopausal Women

NCT00592839
View directory record Official record
Conditions
Nocturnal Vasomotor Symptoms
Interventions
SCE-B, Placebo
Drug
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
17
States / cities
Anaheim, California • Sacramento, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 3 Interventional Results available

Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women

NCT01080300
View directory record Official record
Conditions
Hot Flashes
Interventions
Gabapentin Extended Release, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 63 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mindfulness-Based Stress Reduction for Hot Flashes

NCT01052454
View directory record Official record
Conditions
Vasomotor Symptoms
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2010 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

MsFLASH-01: Escitalopram for Menopausal Symptoms in Midlife Women

NCT00894543
View directory record Official record
Conditions
Hot Flashes, Menopause, Vasomotor Symptoms
Interventions
Escitalopram, Placebo
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
5
States / cities
Oakland, California • Indianapolis, Indiana • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 3 Interventional

A Clinical Trial to Demonstrate the Efficacy and Safety of Cenestin 0.3 mg for the Treatment of Hot Flashes

NCT00272935
View directory record Official record
Conditions
Hot Flashes
Interventions
Cenestin 0.3 mg Tablets, Placebo
Drug · Other
Lead sponsor
Duramed Research
Industry
Eligibility
30 Years to 80 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Huntsville, Alabama • Montgomery, Alabama • Phoenix, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 4, 2026, 4:18 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The DISCOVER INOCA Prospective Multi-center Registry

NCT05288361
View directory record Official record
Conditions
Ischemia and No Obstructive Coronary Artery Disease, Coronary Microvascular Dysfunction, Coronary Vasospasm, Endothelial Dysfunction, Microvascular Angina, Chest Pain With Normal Coronary Angiography
Interventions
Coroventis Coroflow Cardiovascular System and PressureWire™ X Guidewire
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
9
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Not applicable Interventional

Nasal Saline Irrigation After Radiation Therapy for Oropharyngeal Cancer

NCT02338102
View directory record Official record
Conditions
Nasal Obstruction, Rhinitis, Vasomotor, Epistaxis
Interventions
Saline mixture
Other
Lead sponsor
Lisa Shnayder
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 4, 2026, 4:18 AM EDT
Recruiting Phase 2 Interventional

Fezolinetant for Treating Hot Flashes in Men With Prostate Cancer

NCT06972875
View directory record Official record
Conditions
Prostate CA, Androgen Deprivation Therapy
Interventions
Fezolinetant
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

NCT03518138
View directory record Official record
Conditions
Vasomotor Symptoms (VMS)
Interventions
Q-122, Placebo
Drug
Lead sponsor
Que Oncology
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Woodstock, Georgia • Indianapolis, Indiana • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 4, 2026, 4:18 AM EDT
Terminated Phase 3 Interventional Results available

Soy Protein/Effexor Hormone Therapy for Prostate Cancer

NCT00354432
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
oral soy protein/isoflavones powder, Venlafaxine, Placebo Powder, Placebo Pill
Dietary Supplement · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Newark, Delaware • Chicago, Illinois • Decatur, Illinois + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mindfulness Based Stress Reduction for Hot Flashes

NCT00317304
View directory record Official record
Conditions
Hot Flashes, Stress
Interventions
Mindfulness-based stress reduction
Behavioral
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 4 Interventional Results available

Vortioxetine for Menopausal Depression

NCT02234362
View directory record Official record
Conditions
Depression, Menopause, Vasomotor Disturbance, Hot Flashes, Sleep
Interventions
vortioxetine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 62 Years · Female only
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Oct 4, 2026, 4:18 AM EDT
Completed Phase 2 Interventional Results available

Stellate Ganglion Block (SGB) For Women for Breast Cancer

NCT02513329
View directory record Official record
Conditions
Hot Flushes, Hot Flashes
Interventions
Bupivicaine, Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
30 Years to 70 Years · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 4, 2026, 4:18 AM EDT
Recruiting Not applicable Interventional

Men With Prostate Cancer: Optimizing Wellness by Enhanced Relief From Hot Flashes With Acupuncture

NCT07335224
View directory record Official record
Conditions
Hot Flashes, Acupuncture Therapy, Vasomotor Symptoms, Androgen Deprivation Therapy, Prostatic Neoplasms
Interventions
Acupuncture, Lifestyle Management
Other · Behavioral
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older · Male only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 4:18 AM EDT